CD19 and acute lymphoblastic leukemia: The increasing use of anti-CD19 and anti-CD22 immunotherapy in the form of blinatumomab and inotuzumab ozogamicin, respectively, as well as chimeric antigen receptor T cell therapy (CAR-T) for ALL is likely to change the landscape of managing Ph+ ALL in the coming years.